Current Research Studies

Cancer – ANHL1522: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

Condition or Therapy:

Positive Post-Transplant Lymphoproliferative Disease (PTLD)

Category:

Cancer and Blood Disorders
Study Number: ANHL1522

What is the goal of this study?

The main goal of this pilot study is to learn whether it is possible to provide the experimental treatment, LMP-specific T cells (LMP-TC), on time, to children and young adults with Positive Post-Transplant Lymphoproliferative Disease (PTLD) after a solid organ transplant.

Who can join the study?

This study may be a good fit for children and young adults who: 

  • Are younger than 30 years old at the time of enrollment
  • Have a history of solid organ transplantation

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov. 

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.